Esperion Therapeutics (ESPR) Long-Term Investments (2013 - 2019)

Esperion Therapeutics has reported Long-Term Investments for 7 years, with the latest figure at $22.1 million in Q1 2019.

• For the quarter ending Q1 2019, Long-Term Investments fell 47.9% year-over-year to $22.1 million; the trailing twelve-month figure through Mar 2019 stood at $22.1 million (down 47.9% YoY), and the FY2018 full-year result was $243000.0, down 99.67% from the prior year.
• Long-Term Investments for Q1 2019 stood at $22.1 million, up from $243000.0 in the prior quarter.
• The five-year high for Long-Term Investments was $105.7 million in Q3 2017, with the low at $243000.0 in Q4 2018.
• Historically, Long-Term Investments has averaged $49.9 million across 5 years, with a median of $44.6 million in 2015.
• Annual changes were most pronounced in 2015 — Long-Term Investments soared 1616.54% — and 2018, when it slumped 99.67%.
• Esperion Therapeutics' Long-Term Investments stood at $80.3 million in 2015, then sank by 61.52% to $30.9 million in 2016, then surged by 137.56% to $73.4 million in 2017, then tumbled by 99.67% to $243000.0 in 2018, then soared by 8979.42% to $22.1 million in 2019.
• The last three Long-Term Investments figures came in at $22.1 million (Q1 2019), $243000.0 (Q4 2018), and $5.2 million (Q3 2018), per Business Quant data.